natgillin/translations-raw huggingface dataset:
Explanations for higher 5-ALA uptake include a disrupted blood-brain barrier, increased neo-vascularisation, and the overexpression of membrane transporters in glioma tissue. 
Med razlagami za večji privzem 5-ALA so prekinjena krvno-možganska pregrada, povečana neovaskularizacija in čezmerna ekspresija membranskih transportnih proteinov v tkivu glioma.
In a phase III trial with 349 patients with suspected malignant glioma amenable to complete resection of contrast-enhancing tumour were randomised to fluorescence-guided resection after administration of 20 mg/kg body weight 5-ALA HCl or conventional resection under white light. 
V preskušanju III. faze, v katerem je sodelovalo 349 bolnikov, pri katerih so sumili maligni gliom, primernih za popolno resekcijo tumorja z okrepljenim kontrastom, so naključno razporedili v skupino, pri kateri so opravili resekcijo, vodeno s fluorescenco, po uporabi 20 mg 5-ALA HCl/kg telesne mase, ali v skupino, pri kateri so opravili običajno resekcijo pod belo svetlobo.
How to take Gliolan 
Kako jemati zdravilo Gliolan
In a single-arm trial including 21 healthy male volunteers, erythema of the skin could be provoked by direct exposure to UVA light up to 24 hours after oral application of 20 mg/kg body weight 5-ALA HCl. 
V enokračni študiji, v kateri je sodelovalo 21 zdravih moških prostovoljcev, so z neposredno izpostavljenostjo UVA-svetlobi v obdobju 24 ur po peroralni uporabi 20 mg 5-ALA HCl/kg telesne mase lahko izzvali eritem kože.
Unopened bottle 3 years. 
Neodprta steklenica
No trials have been performed in patients with clinically relevant hepatic or renal impairment. 
Raziskav pri bolnikih s klinično pomembno jetrno ali ledvično okvaro niso opravili.
Tel. +49 4103 8006-0 Fax: +49 4103 8006-100 
Tel. + 49 4103 8006 0
Further frequently observed side effects are being sick (vomiting), feeling sick (nausea) and slight increase of some enzymes (transaminases, γ-GT, amylase) or bilirubin (a bile pigment produced in the liver by breakdown of red blood pigment) in the blood. 
Naslednji pogosto opaženi neželeni učinki so bruhanje, občutek slabosti (navzea) in rahlo zvišanje nekaterih encimov (transaminaze, γ-GT, amilaze) ali bilirubina (žolčno barvilo, ki nastaja v jetrih z razpadom barvila rdečih krvničk) v krvi.
Feeling sick (nausea), decrease of blood pressure (hypotension), skin reactions (for example rash, looking like sunburn). 
Občasni neželeni učinki (lahko se pojavijo pri največ 1 od 100 ljudi): Občutek slabosti (navzea), znižanje krvnega tlaka (hipotenzija), kožne reakcije (na primer izpuščaj, ki je videti kot sončna opeklina).
diarrhoea 
diareja
One ml of reconstituted solution contains 23.4 mg of 5-ALA, corresponding to 30 mg 5-ALA HCl. 
En ml rekonstituirane raztopine vsebuje 23,4 mg 5-ALA, kar ustreza 30 mg 5-ALA HCl.
Standard safety pharmacology experiments were performed under light protection in the mouse, rat and dog. 
Pri miših, podganah in psih so izvedli standardne farmakološke poskuse pod zaščito pred svetlobo.
A more pronounced transient increase of liver enzymes without clinical symptoms was observed in the 5-ALA-treated patients. 
Pri bolnikih, ki so prejeli 5-ALA, so opazili izrazitejše prehodno zvišanje jetrnih encimov brez kliničnih simptomov.
hypotension 
hipotenzija
2 bottles 
1 steklenica 2 steklenici 10 steklenic
One ml of reconstituted solution contains 23.4 mg of 5-aminolevulinic acid, corresponding to 30 mg 5-aminolevulinic acid hydrochloride (5-ALA HCl). 
En ml rekonstituirane raztopine vsebuje 23,4 mg 5-aminolevulinske kisline, kar ustreza 30 mg klorida 5-aminolevulinske kisline (5-ALA HCl).
Justification for not including Braille accepted 
PODATKI V BRAILLOVI PISAVI Sprejeta je utemeljitev, da Braillova pisava ni potrebna.
No trials have been performed in patients with poor liver or kidney function. 
Študij pri bolnikih z oslabljenim delovanjem jeter ali ledvic niso opravili.
One bottle contains 1.17 g of 5-aminolevulinic acid (5-ALA), corresponding to 1.5 g 5-ALA HCl. 
Ena steklenica vsebuje 1,17 g 5-aminolevulinske kisline (5-ALA), kar ustreza 1,5 g 5-ALA HCl.
General characteristics 
Splošne značilnosti
An adverse drug reaction of mild nausea was reported in 1 out of 21 volunteers. 
Pri 1 od 21 prostovoljcev so poročali o neželenem učinku zdravila, blagi navzei, ki je bila povezana z jemanjem zdravila.
In a phase I/II trial including 21 patients, a dose-efficacy relationship between the dose levels and the extent and quality of fluorescence in the tumour core was detected: higher doses of 5-ALA enhanced the fluorescence quality and the fluorescence extent of the tumour core compared to demarcation of the tumour core under standard white illumination in a monotone, non-falling fashion. 
Večji odmerki 5-ALA so krepili kakovost in stopnjo fluorescence sredice tumorja v primerjavi z demarkacijo sredice tumorja pod standardno belo osvetlitvijo na enakomeren, nepadajoč način.
Gliolan 30 mg/ml powder for oral solution. 
IME ZDRAVILA Gliolan 30 mg/ml prašek za peroralno raztopino
One case of severe sunburn lasting for 5 days has been reported in a patient after having taken this medicine and a hypericin extract. 
Po sočasni uporabi tega zdravila in ekstrakta hipericina so pri enem bolniku poročali o hudih sončnih opeklinah, ki so trajale 5 dni.
Malignant glioma tissue (WHO-grade III and IV, e.g. glioblastoma multiforme, gliosarcoma or anaplastic astrocytoma) has also been demonstrated to synthesise and accumulate porphyrins in response to 5-ALA administration. 
Pokazali so, da se v tkivu malignega glioma (III. in IV. stopnje po SZO, npr. multiformni glioblastom, gliosarkom ali anaplastični astrocitom) tudi sintetizirajo in kopičijo porfirini kot odziv na uporabo 5-ALA. Koncentracija PPIX je v beli možganovini bistveno manjša kakor v skorji in tumorju.
One bottle contains 1.17 g of 5-aminolevulinic acid, corresponding to 1.5 g 5-aminolevulinic acid hydrochloride (5-ALA HCl). 
Ena steklenica vsebuje 1,17 g 5-aminolevulinske kisline, kar ustreza 1,5 g klorida 5-aminolevulinske kisline (5-ALA HCl).
Four hours after oral administration of 20 mg/kg body weight 5-ALA HCl, the maximum PPIX plasma level is reached. 
Največja koncentracija PPIX v plazmi je dosežena štiri ure po peroralni uporabi 20 mg 5-ALA HCl/kg telesne mase.
brain oedema 
možganski edem
For oral use after reconstitution. 
POSTOPEK IN POT(I) UPORABE ZDRAVILA Za peroralno uporabo po rekonstituciji.
Decrease of blood pressure (hypotension), brain swelling (brain oedema). 
Občasni neželeni učinki (lahko se pojavijo pri največ 1 od 100 ljudi): Znižanje krvnega tlaka (hipotenzija), otekanje možganov (možganski edem).
One bottle contains 1.17 g of 5-aminolevulinic acid (5-ALA), corresponding to 1.5 g 5-aminolevulinic acid hydrochloride (5-ALA HCl). 
KAKOVOSTNA IN KOLIČINSKA SESTAVA Ena steklenica vsebuje 1,17 g 5-aminolevulinske kisline (5-ALA), kar ustreza 1,5 g klorida 5-aminolevulinske kisline (5-ALA HCl).
ANNEX II 
V preskušanju I./II.
Contents of the pack and other information What Gliolan contains 
Shranjevanje zdravila Gliolan Vsebina pakiranja in dodatne informacije
The maximum recommended dosing frequency is once a day. 
Največja priporočena pogostost odmerjanja je enkrat na dan.
The European Commission granted a marketing authorisation valid throughout the European Union for Viagra on 14 September 1998. 
Evropska komisija je dovoljenje za promet z zdravilom Viagra, veljavno po vsej Evropski uniji, izdala 14. septembra 1998.
The main measure of effectiveness was based on the ability of the men to get and maintain an erection. 
Glavno merilo učinkovitosti je bila sposobnost moških doseči in obdržati erekcijo.
The recommended dose of Viagra is 50 mg taken as needed about one hour before sexual activity. 
Priporočeni odmerek zdravila Viagra je 50 mg, ki se vzame po potrebi eno uro pred spolno dejavnostjo.
This was recorded in a special questionnaire completed at home using a scoring system on a five-point scale, where a score of 5 represents the best result. 
To so beležili doma s pomočjo posebnega vprašalnika, v katerem so uporabili pettočkovni sistem točkovanja, pri čemer je bila najvišja vrednost 5 točk.
The full EPAR for Viagra can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Viagra je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Viagra was significantly more effective than placebo in all studies. 
Zdravilo Viagra je bilo v vseh študijah bistveno učinkovitejše od placeba.
What measures are being taken to ensure the safe and effective use of Viagra? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Viagra?
In addition, there were studies in patients with spinal cord injury and with diabetes. 
Poleg tega so bile izvedene študije pri bolnikih s poškodbami hrbtenjače in pri bolnikih s sladkorno boleznijo.
This is a summary of the European public assessment report (EPAR) for Viagra. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Viagra.
The CHMP decided that Viagra's benefits are greater than its risks and recommended that it be given marketing authorisation. 
CHMP je zaključil, da so koristi zdravila Viagra večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
For more information about treatment with Viagra, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Viagra preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
A risk management plan has been developed to ensure that Viagra is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Viagra je bil pripravljen načrt obvladovanja tveganj.
What benefit has Viagra shown during the studies? 
Kakšne koristi je zdravilo Viagra izkazalo med študijami?
Viagra has been studied in four main studies including 1,690 men aged 19 to 87 years, where it was compared with placebo (a dummy treatment) for between 12 and 26 weeks. 
Zdravilo Viagra so proučevali v štirih glavnih študijah, v katerih je sodelovalo 1 690 moških, starih od 19-87 let, in v katerih so zdravilo od 12 do 26 tednov primerjali s placebom (zdravilom brez zdravilne učinkovine).
It is available as tablets (25, 50 or 100 mg) and as orodispersible tablets (50 mg). 
Na voljo je v obliki tablet (25, 50 in 100 mg) in orodisperzibilnih tablet (50 mg).
Viagra is a medicine that contains the active substance sildenafil. 
Viagra je zdravilo, ki vsebuje zdravilno učinkovino sildenafil.
In the fixed-dose studies, the proportions of patients reporting that treatment improved their erections were 62% (25 mg), 74% (50 mg) and 82% (100 mg), compared with 25% on placebo. 
V študiji s fiksnimi odmerki je bil delež bolnikov, ki so poročali o izboljšanju erekcije, 62 % (25 mg), 74 % (50 mg) in 82 % (100 mg) v primerjavi s 25 % bolnikov, ki so jemali placebo.
In the questionnaire, scores for the question on how often the patient was able to achieve intercourse went from about 2 without treatment to 3 or 4 with Viagra 50 mg. 
V vprašalniku, kako pogosto je bolnik sposoben imeti spolne odnose, je bil rezultat brez zdravljenja 2, po jemanju zdravila Viagra v odmerku 50 mg pa 3 ali 4.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Viagra. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Viagra, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Viagra, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila Viagra in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
The orodispersible tablets should be placed on the tongue and left to disintegrate before swallowing. 
Orodisperzibilne tablete se položijo na jezik, kjer se razgradijo, preden jih bolnik pogoltne.
During normal sexual stimulation, cGMP is produced in the penis, where it causes the muscle in the spongy tissue of the penis (the corpora cavernosa) to relax, allowing the flow of blood into the corpora, producing the erection. 
Med normalno spolno stimulacijo nastaja cGMP v penisu, kjer povzroči, da se gobasto tkivo penisa (corpora cavernosa) sprosti, kar omogoči dotok krvi v tkivo (corpora), posledica česar je erekcija.
It must also not be taken by patients who have ever had loss of vision because of a problem with blood flow to the nerve in the eye (non-arteritic anterior ischemic optic neuropathy or NAION). 
Prav tako ga ne smejo jemati bolniki, ki so kadar koli doživeli izgubo vida zaradi težav z dotokom krvi v očesni živec (nearteritična anteriorna ishemična optična nevropatija ali NAION).
The active ingredient in Viagra, sildenafil, belongs to a group of medicines called phosphodiesterase type 5 (PDE5) inhibitors. 
Zdravilna učinkovina v zdravilu Viagra, sildenafil, sodi v skupino zdravil, imenovanih zaviralci fosfodiesteraze tipa 5 (PDE5).
Other information about Viagra 
Druge informacije o zdravilu Viagra:
The most common side effects with Viagra are headache, flushing, dyspepsia (indigestion), visual disorders, including visual colour distortion and blurred vision, nasal congestion (blocked nose), dizziness, nausea and hot flushes. 
Najpogostejši neželeni učinki zdravila Viagra so glavobol, zardevanje, dispepsija (prebavne težave), motnje vida, tudi motnje zaznavanja barv in zamegljen vid, kongestija nosne sluznice (zamašenost nosu), omotica, navzeja in navali vročine.
Viagra must not be taken with nitrates (medicines used to treat angina) or medicines of the class ‘guanylate cyclase stimulators' such as riociguat (used to treat pulmonary hypertension [high blood pressure in the lungs]). 
Viagra se ne sme jemati z nitrati (zdravili za zdravljenje angine pektoris) ali zdravili skupine „stimulatorjev gvanilat-ciklaze“, kot je riociguat (ki se uporablja za zdravljenje pljučne hipertenzije [visokega krvnega tlaka v pljučih]).
If Viagra is taken with food, the onset of activity may be delayed compared with taking it without food. 
Če se zdravilo Viagra zaužije s hrano, lahko začne delovati pozneje, kot če se zaužije brez nje.
Viagra is used to treat adult men with erectile dysfunction (sometimes called impotence), when they cannot get or keep a sufficiently hard penis (erection) for satisfactory sexual activity. 
Zdravilo Viagra se uporablja za zdravljenje erektilne disfunkcije (imenovane tudi impotenca) pri odraslih moških, kadar ne zmorejo doseči ali ohraniti takšne erekcije penisa, ki omogoča zadovoljivo spolno dejavnost.
It works by blocking the phosphodiesterase enzyme, which normally breaks down a substance known as cyclic guanosine monophosphate (cGMP). 
Deluje tako, da zavira encim fosfodiesterazo, ki običajno razgrajuje snov, imenovano ciklični gvanozinmonofosfat (cGMP).
By blocking the breakdown of cGMP, Viagra restores erectile function. 
Zdravilo Viagra z zaviranjem razgradnje cGMP ponovno vzpostavi erektilno funkcijo.
What is the risk associated with Viagra? 
Kakšna tveganja so povezana z zdravilom Viagra?
Two of these studies used fixed doses (patients allocated to 25, 50 or 100 mg) and two studies were flexible (patients started on 25 mg and could be moved to 50 or 100 mg depending on their response). 
V dveh študijah so bili uporabljeni fiksni odmerki (bolniki so dobivali 25, 50 ali 100 mg), v dveh pa so odmerke prilagajali (bolniki so začeli s 25-miligramskim odmerkom, nato pa so lahko prejeli 50- ali 100-miligramski odmerek, odvisno od njihovega odziva).
For the full list of all side effects reported with Viagra, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Viagra, glejte navodilo za uporabo.
Why has Viagra been approved? 
Zakaj je bilo zdravilo Viagra odobreno?
Viagra must not be used where sexual activity is inadvisable (e.g. men with severe heart disease such as unstable angina or severe heart failure). 
Ne smejo ga uporabljati osebe, ki jim je spolna aktivnost odsvetovana (npr. moški s hudimi obolenji srca, kot sta nestabilna angina pektoris ali hudo srčno popuščanje).
Because Viagra has not been studied in patients with severe liver disease, hypotension (low blood pressure), recent stroke or myocardial infarction (heart attack), or a hereditary eye disease, such as retinitis pigmentosa, these patients must not use it. For the full list of restrictions, see the package leaflet. 
Zdravila Viagra niso proučevali pri bolnikih z resnimi obolenji jeter, hipotenzijo (nizkim krvnim tlakom), nedavno možgansko kapjo ali miokardnim infarktom (srčnim napadom) ali dedno očesno boleznijo, kot je na primer retinitis pigmentosa, zato ti zdravila ne smejo jemati.
The dose may be increased to a maximum of 100 mg or decreased to 25 mg depending on the effectiveness and side effects. 
Odmerek zdravila se lahko glede na učinkovitost in neželene učinke poveča na največ 100 mg ali zmanjša na 25 mg. Bolniki z jetrnimi obolenji ali resnimi motnjami v delovanju ledvic naj začnejo zdravljenje s 25-miligramskim odmerkom.
What is Viagra used for? 
Za kaj se zdravilo Viagra uporablja?
For Viagra to be effective, sexual stimulation is required. 
Zdravilo Viagra je učinkovito le ob spolnem vzburjenju.
How does Viagra work? 
Kako zdravilo Viagra deluje?
How has Viagra been studied? 
Kako je bilo zdravilo Viagra raziskano?
How is Viagra used? 
Kako se zdravilo Viagra uporablja?
What is Viagra? 
Kaj je zdravilo Viagra?
The correct dose should be mixed into a small amount of food. 
Ustrezen odmerek je treba zmešati z majhno količino hrane.
Treatment may be repeated at 24 hour intervals during 10 consecutive days. 
Zdravljenje se lahko ponovi vsakih 24 ur in lahko traja 10 zaporednih dni.
Bioavailability after oral administration is about 60%. 
Biološka uporabnost po peroralnem dajanju je približno 60-odstotna.
Therefore horses should be monitored frequently during the treatment period. 
Zato je treba konje med zdravljenjem pogosto pregledovati.
The excipients listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required, or considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product. 
Pomožne snovi, navedene v poglavju 6.1 SPC, so bodisi dovoljene snovi, za katere tabela 1 priloge Uredbe Komisije (EU) št. 37/2010 določa, da MRL ni potreben ali pa ne spadajo v področje uporabe Uredbe (ES) št. 470/2009, kadar so uporabljene tako kot v tem zdravilu za uporabo v veterinarski medicini..
The treatment should be combined with environmental control. 
Zdravljenje je treba kombinirati z okoljskimi ukrepi.
Each case should be assessed individually by the veterinarian and an appropriate treatment program determined. 
Veterinar mora oceniti vsak primer posebej in določiti ustrezen program zdravljenja.
Dosage in medium to long term use should therefore generally be kept to the minimum necessary to control symptoms. 
Zato je treba pri srednjeročni in dolgoročni uporabi običajno dajati najmanjši odmerek, ki je potreben za obvladovanje simptomov.
Excretion of prednisolone is complete within 3 days. 
Prednizolon se v celoti izloči v 3 dneh.
The overall average Tmax is 2.5 ± 3.1 hours, Cmax is 237 ± 154 ng/ml and AUCt is 989 ± 234 ng∙h/ml. 
Skupni povprečni Tmax je 2,5 ± 3,1 ure, Cmax je 237 ± 154 ng/ml, AUCt pa 989 ± 234 ng∙h/ml.
Excessive sweating has been very rarely observed. 
Prekomerno potenje je bilo zelo redko opaženo.
T½ is 3.1 ±2.3 hours but is not meaningful from a therapy standpoint when evaluating systemic corticosteroids. 
T½ je 3,1 ± 2,3 ure, vendar pri oceni sistemskih kortikosteroidov z vidika zdravljenja ni pomemben.
Other gastrointestinal symptoms that have been very rarely observed are colic and anorexia. 
Drugi znaki gastrointestinalnega trakta, ki so bili zelo redko opaženi, sta kolika in anoreksija.
THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable 
BESEDILO „SAMO ZA ŽIVALI“ IN POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE, ČE JE SMISELNO
Meat and offal: 10 days. 
Meso in organi: 10 dni.
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE 
B. POGOJI TER OMEJITVE GLEDE OSKRBE IN UPORABE
Because corticosteroids can reduce the immunoresponse to vaccination, prednisolone should not be used in combination with vaccines or within two weeks after vaccination. 
Kortikosteroidi lahko zmanjšajo imunski odziv na cepiva, zato se prednizolon ne sme uporabljati v kombinaciji s cepivi oziroma še dva tedna po cepljenju.
Following oral administration in horses prednisolone is readily absorbed giving a prompt response which is maintained for approximately 24 hours. 
Po peroralnem dajanju se prednizolon pri konjih hitro absorbira, tako da sproži hiter odziv, ki se ohrani še približno 24 ur.
4 μg/kg 8 μg/kg 6 μg/kg 15 μg/kg 
4 μg/kg 8 μg/kg 6 μg/kg 15 μg/kg mišica maščoba jetra ledvice
The active substance in Equisolon is an allowed substance as described in table 1 of the annex to Commission Regulation (EU) No 37/2010: 
C. NAVEDBA NAJVIŠJIH DOVOLJENIH KOLIČIN OSTANKOV ZDRAVILA (MRL) Učinkovina v zdravilu Equisolon je dovoljena učinkovina, kot je navedena v tabeli 1 (dovoljene snovi) priloge Uredbe Komisije (EU) št. 37/2010:
Because of the pharmacological properties of prednisolone, use with caution when the veterinary medicinal product is used in animals with a weakened immune system. 
Zaradi farmakoloških lastnosti prednizolona je potrebna previdnost, kadar se zdravilo uporablja pri živalih z oslabljenim imunskim sistemom.
A significant increase in triglycerids occurs very commonly. 
Zelo pogosto se pojavi precejšnje zvišanje ravni trigliceridov.
Do not use during pregnancy. 
Ne uporabite v obdobju brejosti.
This can be a part of possible iatrogenic hyperadrenocorticism (Cushings disease) involving significant alteration of fat, carbohydrate, protein and mineral metabolism, e.g. redistribution of body fat, increase in body weight, muscle weakness and wastage and osteoporosis may result. 
To je lahko del možnega iatrogenega hiperadrenokorticizma (Cushingove bolezni), za katerega so značilne precejšnje spremembe v presnovi maščob, ogljikovih hidratov, beljakovin in mineralov; pojavijo se lahko na primer prerazporeditev telesnih maščob, povečanje telesne mase, šibkost mišic in zmanjšanje mišične mase ter osteoporoza.
Very rarely urticaria has been observed. 
Zelo redko je bila opažena urtikarija.
Multiple dosing does not result in plasma accumulation of prednisolone. 
Večkratno odmerjanje ne povzroči kopičenja prednizolona v plazmi.
Shelf life of the veterinary medicinal product as packaged for sale: 3 years Sachets are for single use and should be disposed after use/opening. 
Rok uporabnosti zdravila v pakiranju za prodajo: 3 leta Vrečke so namenjene za enkratno uporabo in jih je po uporabi/odpiranju treba zavreči.
Bodyweight (kg) of horse 
Telesna masa (kg) konja
DOSAGE FOR EACH SPECIES, ROUTE AND METHOD OF ADMINISTRATION 
ODMERKI ZA POSAMEZNE ŽIVALSKE VRSTE TER POT IN NAČIN UPORABE ZDRAVILA
THE WORDS “FOR ANIMAL TREATMENT ONLY” 
BESEDILO „SAMO ZA ŽIVALI“
Sachets of different pack size can be combined to achieve the correct dose, as per the table below: 
Ustrezen odmerek je mogoče doseči s kombiniranjem vrečk različnih velikosti, kot je navedeno v spodnji tabeli:
Do not use this veterinary medicinal product after the expiry date which is stated on the label and the carton after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na ovojnini in zunanji ovojnini poleg oznake EXP.
A measuring spoon is included. 
Priložena je merilna žlička.